Company profile
Spyre Therapeutics, Inc.
NASDAQ: SYRE · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
64CFH 69DQ 68GM 38SS 69
v0.1 · 65/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ 3-yr revenue growth, Piotroski F
Methodology →Revenue TTM
$90.5M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$155.2M
Employees
102
as of 2026-08-07
Market cap
$9.0B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$155.2M-$155.2M2025
Operating income-$209.6M-$209.6M2025
Total assets$777.8M$777.8M2025
Liabilities$62.5M$62.5M2025
Equity$715.2M$715.2M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2023
By product
License0%
By geography
Not disclosed.
The read
What is Spyre Therapeutics, Inc.’s revenue?
Spyre Therapeutics, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Goldenwell Biotech, Inc.16DRevolution Medicines, Inc.52DSummit Therapeutics Inc.49DPraxis Precision Medicines, Inc.61COruka Therapeutics, Inc.66BScholar Rock Holding Corporation39DNeighbors
Middlesex →Key facts
CEOCameron Turtle
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: SYRE
Employees102
IPO date2016-04-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.